NCT01329705撤回不适用
Dynamic Splinting for Excessive Plantarflexion in Patients With Spastic Hemiplegia: A Randomized, Controlled Study of Gait Analysis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 撤回
- 试验地点
- 2
- 主要终点
- Change in gait pattern
研究概览
简要总结
The purpose of this study is to examine the effectiveness of onabotulinum toxin A (BTX) injections (tone management) and dynamic splinting (contracture reduction) for improving gait patterns in patients with spastic hypertnoia due to stroke or traumatic brain injury and resultant excessive plantarflexion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients enrolled will be male or female, be at least 18 years of age, and have been diagnosed with spastic hemiplegia and excessive plantarflexion, which includes the following:
- •Diagnosis of a stroke or traumatic brain injury more than 6 months prior to enrollment in this study
- •Reduced AROM and PROM in ankle dorsiflexion
- •Ability to ambulate safely 20 feet without an ankle-foot orthosis (AFO)
- •Inability to ambulate with initial heel-contact
- •No prior BTX treatment within 6 months
- •R1 of -10° or greater (using the Tardeiu method of assessment)
- •Mean Ashworth Scale Test ≥3 for plantarflexors
排除标准
- •Bell's Palsy
- •Viral Encephalitis
- •Muscular Dystrophy
- •Multiple Sclerosis
- •Prior heel-cord lengthening or tendon-transfer procedure in the foot/ankle
- •Subjects with a fixed contracture of the ankle
- •Female subjects who are pregnant (positive urine pregnancy test), who have an infant they are breastfeeding, or are of childbearing potential and do not practice a reliable method of birth control
- •Bleeding disorders
- •Diagnosis of a disease that may interfere with neuromuscular function (ie. Myasthenia Gravis, Lambert-Eaton Myasthenic Syndrome, amyotrophic lateral sclerosis)
- •Subjects currently using aminoglycoside antibiotics, curare-like agents, or other agents that may interfere with neuromuscular function
- •Subjects with profound weakness or atrophy of the muscles in the target areas of injection
- •Active systemic infection or infection at the injection site
- •Allergy or sensitivity to botulinum toxin A
结局指标
主要结局
Change in gait pattern
时间窗: 12 weeks
次要结局
未报告次要终点
研究者
研究点 (2)
Loading locations...
相似试验
撤回
不适用
Dynamic Splinting for Excessive Pronation Following CVAPronation ContractureNCT00900692Dynasplint Systems, Inc.
Unknown
不适用
Botulinum Toxin A to Treat Flexion Contracture After Total Knee ArthroplastyFlexion Contracture Following Total Knee ReplacementNCT01829087Rothman Institute Orthopaedics140
Unknown
2 期
Botulinum Toxin Type A for Foot Dystonia-associated Pain in Parkinson's DiseaseDystonia DisorderParkinson DiseaseNCT04277247University of Calgary40
已完成
3 期
Study of Botulinum Toxin and Recovery of Hand Function After StrokeStroke With HemiparesisNCT01422161NYU Langone Health16
已完成
不适用
Muscle Selection for Botulinum Toxin A Injection in Poststroke Elbow Flexor SpasticityMuscle SpasticityNCT04036981Izmir Katip Celebi University55